文献速递间质性肺疾病

吡非尼酮对特发性肺纤维化患者死亡率影响的汇总分析与荟萃分析

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
PubMed 文献 · Lancet Respir Med · 2016-11-19

本研究对三项全球随机3期试验(CAPACITY 004/006和ASCEND 016)进行汇总分析,并纳入两项日本试验(SP2和SP3)进行荟萃分析,比较吡非尼酮与安慰剂对特发性肺纤维化患者死亡率的影响。

要点

  • 120周内治疗中出现的不良事件相关死亡风险也显著低于安慰剂。

核心结论

  • 多种分析方法表明,与安慰剂相比,吡非尼酮治疗可降低特发性肺纤维化患者120周内的相对死亡风险。

研究设计与样本

  • 汇总分析合并了三项全球随机3期试验(CAPACITY 004和006,ASCEND 016)的吡非尼酮组与安慰剂组患者数据。
  • 荟萃分析纳入了上述三项试验及两项日本试验(SP2和SP3)的数据。

临床怎么用

  • 对于特发性肺纤维化患者,吡非尼酮治疗与安慰剂相比可显著降低52周及120周内的死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are low. Thus prospective mortality trials are logistically very challenging, justifying the use of pooled analyses or meta-analyses. We did pooled analyses and meta-analyses of clinical trials of pirfenidone versus placebo to determine the effect of pirfenidone on mortality outcomes over 120 weeks. METHODS: We did a pooled analysis of the combined patient populations of the three global randomised phase 3 trials of pirfenidone versus placebo-Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY 004 and 006; trial durations 72-120 weeks) and Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND 016; 52 weeks)-for all-cause mortality, treatment-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-related mortality, and treatment-emergent idiopathic-pulmonary-fibrosis-related mortality at weeks 52, 72, and 120. We also did meta-analyses of these data and data from two Japanese trials of pirfenidone versus placebo-Shionogi Phase 2 (SP2) and Shionogi Phase 3 (SP3; trial durations 36-52 weeks). FINDINGS: At week 52, the relative risk of death for all four mortality outcomes was significantly lower in the pirfenidone group than in the placebo group in the pooled population (all-cause mortality hazard ratio [HR] 0·52 [95% CI 0·31-0·87; p=0·0107]; treatment-emergent all-cause mortality 0·45 [0·24-0·83; 0·0094]; idiopathic-pulmonary-fibrosis-related mortality 0·35 [0·17-0·72; 0·0029]; treatment-emergent idiopathic-pulmonary-fibrosis-related mortality 0·32 [0·14-0·76; 0·0061]). Consistent with the pooled analysis, meta-analyses for all-cause mortality at week 52 also showed a clinically relevant and significant risk reduction in the pirfenidone group compared with the placebo group. Over 120 weeks, we noted significant differences in the pooled analysis favouring pirfenidone therapy compared with placebo for treatment-emergent all-cause mortality (p=0·0420), idiopathic-pulmonary-fibrosis-related mortality (0·0237), and treatment-emergent idiopathic-pulmonary-fibrosis-related (0·0132) mortality; similar results were shown by meta-analyses. INTERPRETATION: Several analytic approaches demonstrated that pirfenidone therapy is associated with a reduction in the relative risk of mortality compared with placebo over 120 weeks. FUNDING: F Hoffmann-La Roche/Genentech.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2016. PMID: 27876247. doi:10.1016/S2213-2600(16)30326-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。